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Inadequate antibiotic therapy, generally defined as microbiologically ineffective anti-infective therapy against the causative
pathogen, can influence patient outcome. However, the detrimental effects of inadequate antibiotic therapy seem to become
weaker in the most severely ill patients with short life expectancies. In addition to severity of illness, other methodological
issues should be carefully examined in studies assessing the excess mortality due to inadequate therapy. To adjust for
confounding as much as possible in order to obtain an unbiased estimate of the magnitude of the effect of inadequate therapy
is a key methodological challenge for future research. With regard to the choice of antibiotic agents, b-lactam and amino-
glycoside combination therapy does not seem to improve clinical outcome in most cases of sepsis caused by gram-negative
bacteria, including Pseudomonas aeruginosa bacteremia. A potential benefit of combination therapy in the treatment of severe
pneumococcal sepsis has been suggested in several observational studies, but recently published data have disputed this
hypothesis. Finally, better risk scores and laboratory tools are urgently needed to improve the adequacy of empirical antibiotic
therapy and patient outcomes.
Frapper fort et frapper vite. (Hit hard and fast.)
—Paul Ehrlich, address to the 17th International Congress of Medicine, 1913 [1]
Although antibiotic properties of molds and other natural sub-
stances had already been described by several scientists at the
end of the 19th century, systemically administered antibiotic
agents were not introduced into clinical practice until the 1930s.
A controlled study published in 1938 showed the survival benefit
of sulfonamide therapy, which reduced mortality from 27% (con-
trol group) to 8% (treatment group) among patients with lobar
pneumonia [2]. Other life-threatening infections responded less
robustly, and sulfonamide resistance developed rapidly. In No-
vember 1942, penicillin made its first highly acclaimed clinical
appearance in the United States, when it was used for treating
victims of the Cocoanut Grove fire in Boston, Massachusetts.
Received 12 July 2006; accepted 11 September 2006; electronically published 27 November
2006.
Presented in part: 45th Annual Interscience Conference on Antimicrobial Agents and
Chemotherapy, Washington, DC, 17 December 2005 (plenary lecture; abstract 1132).
Reprints or correspondence: Dr. Stephan Harbarth, Infection Control Program, Geneva
University Hospitals, 24 rue Micheli-du-Crest, CH-1211 Geneva, Switzerland (stephan.harbarth
@hcuge.ch).
Clinical Infectious Diseases 2007; 44:87–93
 2006 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2007/4401-0016$15.00
The availability of antimicrobial agents has become crucial for
modern medicine. Although other public health measures have
contributed to increasing life expectancy over the past century,
antibiotics have helped to save innumerable lives and to reduce
morbidity associated with infections. The success of antibiotics
bred their overuse. An increasing prevalence of antibiotic resis-
tance has led to the progressive decrease in the effectiveness of
narrow-spectrum agents and to an increase in difficult-to-treat
infections. More then ever, selection of the most appropriate
antibiotic therapy has become a challenge for clinicians.
Appropriate antibiotic use is commonly defined as the use of
an antimicrobial agent that is correct on the basis of all available
clinical, pharmacological, and microbiological evidence. It in-
cludes narrowing the spectrum when culture and phenotypic
results are available, using appropriate dosages and dosing in-
tervals, and respecting additional principles of the judicious pre-
scription of antibiotics [3]. Inadequate antibiotic therapy, gen-
erally defined as the microbiological documentation of an
infection with a causative pathogen that is not being effectively
treated, can influence patient outcome [4]. On the basis of a
selection of relevant articles, in the present overview, we discuss
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Table 1. Prognostic factors in patients with ventilator-associ-
ated pneumonia, according to multivariate analysis of the inter-
action between severity of illness and adequacy of early anti-
biotic therapy.
Prognostic factor OR (95% CI)
McCabe score
Nonfatal 1
Fatal 3.4 (1.5–7.6)
LOD score
4
With adequate AT 1
With inadequate AT 7.2 (1.5–35.5)
14
With adequate AT 24.9 (4.8–129)
With inadequate AT 16.5 (2.5–110)
NOTE. Data are from [15]. AT, antibiotic therapy; LOD, logistic organ
dysfunction.
some of the challenges associated with selecting microbiologically
adequate therapy, as well as its effect on patient outcome. More
specifically, we address the following questions:
1. What is the impact of microbiologically inadequate an-
tibiotic therapy on survival rate and cure rate? What is the
magnitude of the benefit associated with the timely use of ef-
fective therapy in critically ill patients?
2. What are commonly encountered methodological chal-
lenges in observational studies examining the magnitude of this
effect? Which methodological issues should be addressed in
future research to resolve some important controversies?
3. What constitutes optimal therapy in selected clinical cir-
cumstances? In particular, (a) is empirical coverage of certain
“low-virulence” pathogens (e.g., Enterococcus species and Can-
dida species) necessary, and (b) is combination therapy needed
for certain types of bacterial infections?
IMPACT OF MICROBIOLOGICALLY
INADEQUATE ANTIBIOTIC THERAPY
ON SURVIVAL AND CURE RATE
Microbiologically inadequate antimicrobial therapy is an im-
portant determinant of outcome in patients with severe infec-
tion [4, 5]. A landmark study conducted in the early 1960s
demonstrated that microbiologically adequate antimicrobial
therapy leads to a case-fatality rate among patients with gram-
negative bacteremia that is lower than that among similar pa-
tients receiving inadequate therapy [6]. More recently, Gar-
rouste-Orgeas et al. [7] have shown a favorable impact of early
adequate antimicrobial therapy on outcome among patients
with intensive care unit–acquired bloodstream infection. In that
study, in-hospital mortality among patients who received ad-
equate antibiotic therapy 11 day after blood culture sampling
(OR, 4.1; 95% CI, 2.2–7.7) was higher than that among patients
treated earlier (OR, 2.7; 95% CI, 1.89–4.1). Similarly, other
studies have demonstrated that inadequate antimicrobial ther-
apy is an independent risk factor for death among critically ill
patients with severe infection [5, 8].
The magnitude of benefit associated with the timely use of
effective therapy for critically ill patients may depend on the
causative pathogen and population studied. In a study of ep-
isodes of Staphylococcus aureus bacteremia, Lodise et al. [9]
showed that delayed antibiotic therapy (12 days after positive
culture results) was an independent predictor of infection-re-
lated mortality (OR, 3.8; 95% CI, 1.3–11). In another study
involving critically ill patients with cancer, in-hospital mortality
was higher when antibiotic therapy was initiated 12 h after
diagnosis (OR, 7.05; 95% CI, 1.17–42.21) [10]. Iregui et al.
[11] demonstrated that even microbiologically adequate but
initially delayed (124 h after meeting the diagnostic criteria)
antibiotic therapy for ventilator-associated pneumonia was in-
dependently associated with higher mortality. These data were
reinforced by the results of a recently published cohort study
of patients with septic shock that showed that each hour of
delay in antimicrobial administration over the ensuing 6 h after
the onset of hypotension was associated with an average de-
crease in survival of 8% [12].
In contrast, in a large study, Bryan et al. [13] showed that
early antibiotic selection for the first 24 h did not influence
survival, regardless of the adequacy of the antibiotics selected.
However, this latter study showed improved survival among
patients receiving adequate antibiotics after the first day of
therapy. A lack of association between microbiologically in-
adequate therapy and increased mortality has been observed
by others [14], but this can be explained by (1) the inclusion
of patients with non–life-threatening infections (e.g., surgical
site infections and community-acquired methicillin-resistant S.
aureus infection), (2) methodological limitations (e.g., small
sample size), or (3) the influence of confounding factors and
bias (e.g., inclusion of patients with rapidly fatal disease and a
very high severity of illness). For instance, a study investigating
the interaction between disease severity and efficacy of anti-
biotic therapy in 142 critically ill patients with ventilator-
associated pneumonia showed that inadequate empirical ther-
apy was associated with a poor prognosis only in patients with
moderate severity of illness (table 1) [15]. Conversely, for the
group of patients who were most severely ill, neither the ad-
equacy of initial therapy nor the duration of inadequate therapy
influenced survival.
Even in the absence of a direct effect on mortality, micro-
biologically inadequate antibiotic therapy influences the failure
rate. This has been shown for a wide range of infections and
is often associated with the presence of antibiotic-resistant path-
ogens. For example, the use of trimethoprim-sulfamethoxazole
to treat community-acquired urinary tract infections or pneu-
monia caused by trimethoprim-sulfamethoxazole–resistant mi-
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Figure 1. Influence of antibiotic resistance on cure rates for acute
uncomplicated pyelonephritis in women: comparison of ciprofloxacin (7
days) and trimethoprim-sulfamethoxazole (TMP-SMX) (14 days) [17].
croorganisms increases the likelihood of clinical failure (figure
1) [16, 17].
METHODOLOGICAL ISSUES: AN EXAMPLE
FROM THE LITERATURE
Important methodological challenges should be considered when
interpreting the currently available evidence on the association
between microbiologically inadequate antimicrobial therapy and
patient outcome. This research question is not amenable to test-
ing in a randomized trial, because it would be unethical to know-
ingly expose patients to inadequate therapy. Thus, the answer to
this question relies on observational studies. Obviously, it is un-
likely that inadequate antimicrobial therapy does have some ben-
eficial effect on patient outcome. The key objective of an ob-
servational study, then, is to remove as many confounding factors
as possible to obtain an unbiased estimate of the magnitude of
the effect of inadequate therapy [18].
In one such widely cited study of patients with intensive care
unit–acquired bloodstream infection, the crude relative risk
(RR) for mortality after microbiologically inadequate therapy,
compared with adequate antimicrobial therapy, equaled 2.2,
corresponding to a crude OR of 4.1 [19]. By use of a multi-
variable logistic regression model, an adjusted OR of 6.9 was
estimated for the effect that inadequate antimicrobial therapy
for bloodstream infection has on in-hospital mortality, after
including the use of vasopressors, age, organ dysfunctions, and
severity of illness as variables along with inadequate therapy.
A major limitation of this analysis was that the factors included
in the logistic regression model were only those found to be
significantly associated with mortality. A stepwise variable se-
lection approach was used, with a P value of .05 used as the
limit for the acceptance or removal of new terms. The problem
is that this method does not remove confounding by factors
not selected into the model. Many characteristics were iden-
tified that distinguished patients receiving microbiologically in-
adequate antimicrobial therapy from those receiving adequate
antimicrobial therapy, such as time spent in the hospital before
bloodstream infection and prior use of antimicrobials [19].
Presumably, these factors influenced the probability of inade-
quate therapy and were also associated with the outcome, al-
though not always to a statistically significant degree. The non-
inclusion of these variables in the model likely contributed to
an overestimation of the effect of inadequate therapy [18, 19].
Observational research on the effect of inadequate therapy
is limited by the possibility of residual confounding due to
unmeasured variables. The key point is that confounding fac-
tors do not have to be statistically significantly associated with
the outcome to be confounding factors. Instead of focusing on
statistical significance, the analysis should be directed toward
a careful consideration of the potential sources of confounding
and deriving the least biased estimate of the true causal effect
[18]. Unfortunately, automated variable-selection methods
completely ignore the relationship between the putative con-
founding factors and the exposure.
One analytic method that has gained widespread application
in overcoming problems with confounding is the use of pro-
pensity scores. In our context, the propensity score would be
the probability (0.0–1.0) of each patient receiving inadequate
therapy [5]. After determining the propensity score for each
patient by use of the predicted probability of exposure to in-
adequate antimicrobial therapy, this covariate can then be in-
cluded along with other confounding variables in the multi-
variate analysis, which may allow for further adjustment for
differences between patients who received or did not receive
adequate initial antimicrobial therapy [20].
EMPIRICAL COVERAGE OF SPECIFIC
“LOW-VIRULENCE” PATHOGENS
Microorganisms that had traditionally been considered to be
of low virulence, such as Candida species, Enterococcus species,
Acinetobacter baumannii, and coagulase-negative staphylococci,
are an increasingly important cause of nosocomial infections.
Therefore, the question arises as to whether antibiotic coverage
against these pathogens should be included in the empirical
coverage of certain infections.
The clinical significance of enterococci has been the subject
of long-lasting debate. In particular, their role as primary path-
ogens in polymicrobial intra-abdominal infections remains
controversial. Although animal models have shown that mono-
microbial, intra-abdominal enterococcal infections have limited
pathogenicity, several studies have suggested that the presence
of enterococci increases the postoperative complication rate and
risk of death in certain patient groups [21]. Among patients
with monomicrobial enterococcal bacteremia, receipt of effec-
tive antimicrobial therapy within 48 h independently predicted
90 • CID 2007:44 (1 January) • HEALTHCARE EPIDEMIOLOGY
Table 2. Potential mechanisms explaining the suggested benefit
of combination therapy for severe, bacteremic pneumococcal
pneumonia.
Immunomodulating effect of macrolides
Effect on atypical pathogens in mixed infections
Improved bactericidal effect
Decreased emergence of resistance
Variable protein binding and decreased activity of ceftriaxone
in severe sepsis
Figure 2. Survival curve for patients with severe pneumococcal sepsis,
stratified by receipt of antibiotic monotherapy ( ) versus combinationnp 25
therapy ( ) [35]. The risk of death was almost identical after thenp 82
number of organ dysfunctions and the severity of illness at baseline were
adjusted for (adjusted hazard ratio [HR], 1.1; 95% CI, 0.4–3.1; ).Pp .9
survival [22]. In an extensive literature review [23], we sum-
marized available evidence arguing in favor of using empirical
therapy with enterococcal coverage in the following cases: (1)
immunocompromised patients with nosocomial peritonitis and
severe sepsis who have previously received broad-spectrum an-
tibiotics (e.g., cephalosporins) selecting for Enterococcus spe-
cies, and (2) patients with peritonitis and valvular heart disease
or prosthetic intravascular material, which place them at high
risk for endocarditis.
Delay in initiating antifungal treatment for critically ill pa-
tients may also be associated with worse outcomes [24]. Because
no accurate tools for early diagnosis are yet available, many
researchers recommend early empirical antifungal therapy for
nonneutropenic patients when candidiasis is suspected [25].
Clinical algorithms and risk scores may help to identify the
patients at highest risk for candidiasis [25]. There are several
options for early empirical and preemptive treatment of can-
didemia in nonneutropenic patients, including amphotericin
B, fluconazole, voriconazole, and echinocandins. A recent study
has suggested that voriconazole was as effective as a regimen
of amphotericin B followed by fluconazole in the treatment of
candidemia in nonneutropenic patients [26]. However, as was
outlined in an accompanying editorial [27], the study had sev-
eral limitations (e.g., relevance of the control group and bi-
ased selection of patients) that limit its clinical relevance and
generalizability.
Infections with A. baumannii are now endemic in many
countries. Although generally less virulent than Pseudomonas
aeruginosa, A. baumannii has nonetheless become a problematic
pathogen because of increasing resistance to commonly used
antimicrobial agents. Because bacteremia due to A. baumannii
managed with microbiologically inadequate therapy is associated
with increased mortality, the intravenous use of polymyxins has
reemerged worldwide [28]. Subsequently, physicians are facing
the difficult decision of when to institute therapy with poly-
myxins. At present, clinical evidence does not allow for any firm
conclusions about the effectiveness of empirical use of colistin,
because the optimal therapeutic regimen for these multidrug-
resistant infections remains to be determined.
The increasing use of intravascular catheters contributes to
the high incidence of health care–associated infections with
coagulase-negative staphylococci (CoNS). In daily practice, it
remains a challenge to distinguish clinically significant CoNS
from contaminant strains. Because 180% of CoNS are resistant
to methicillin, vancomycin appears to be the mainstay of di-
rected treatment for CoNS infections, in addition to removal
of infected foreign bodies [29]. Combination therapy, usually
by adding rifampicin or gentamicin, seems to be helpful for
the treatment of some deep-seated infections with CoNS,
mainly prosthetic valve endocarditis. Current guidelines, how-
ever, do not recommend specific coverage of CoNS for em-
pirical treatment of severe sepsis.
COMBINATION THERAPY FOR SEPSIS CAUSED
BY GRAM-NEGATIVE BACTERIA
As is mentioned above, early adequate therapy reduces mor-
tality associated with gram-negative bacteremia. Nevertheless,
there is no consensus regarding the need to use combination
as opposed to single-agent antimicrobial therapy to treat these
infections. In theory, combination therapy has the following
potential advantages: (1) an additive or even synergistic effect
in vitro, (2) broader antibacterial coverage for potentially mul-
tidrug-resistant microorganisms, and (3) a preventive effect on
the emergence of resistance in certain gram-negative bacteria.
However, concerns regarding toxicity, costs, and detrimental
drug interactions should be considered. In addition, the avail-
ability of potent broad-spectrum antimicrobials may render
combination therapy unnecessary. Lastly, there are no clinical
data showing an undisputable advantage of combination ther-
apy over monotherapy in the treatment of sepsis caused by
gram-negative bacteria.
In a systematic review of controlled trials, Paul et al. [30]
compared b-lactam monotherapy with b-lactam and amino-
glycoside combination therapy in the treatment of gram-neg-
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Table 3. Issues that should be addressed in future research to resolve important controversies and decrease major deficits in our
knowledge of optimal antimicrobial therapy for critically ill patients.
Study type, research topic Need Comment
Intervention studies
Effect of combination therapy on
severe pneumococcal pneumonia
Randomized clinical trial Enrollment requires microbiological test results.
Molecular techniques for rapid identification of
pneumococcal infection might facilitate patient
inclusion.
Clinical effectiveness of rapid
microbiological tools to increase
the early adequacy of therapy
Randomized clinical trial Current procedures for approval of PCR-based
diagnostic tools do not require randomized studies,
despite an urgent need to demonstrate their
clinical effectiveness.
Observational studies
Magnitude of the effect of delayed
microbiologically adequate therapy
Accurate multivariate modelling Use of propensity scores and advanced statistical
analyses may generate unbiased effect estimates
Effect of combination therapy on
Pseudomonas aeruginosa
bacteremia
Multicenter, observational cohort
studies
Randomised clinical trial unlikely ever to be
performed. Pooled analysis of clinical trials
investigating new sepsis drugs may provide
meaningful observational evidence.
Empirical coverage of “low-virulence”
pathogens
Prediction tools and risk score models Better risk scores are urgently needed to identify
patients at high risk of infection with these bacteria
ative bacteremia. Sixty-four trials comprising 7586 subjects
were included in the analysis, which showed no significant
difference between mortality associated with monotherapy and
that associated with combination therapy (RR, 0.90; 95% CI,
0.77–1.06). Moreover, monotherapy tended to be protective
against clinical failure (RR, 0.87; 95% CI, 0.78–0.97) and mi-
crobiological failure (RR, 0.86; 95% CI, 0.72–1.02). The analysis
of subgroups did not show any firm advantage of combination
therapy over monotherapy for P. aeruginosa infection or for
infection with gram-negative versus gram-positive bacteria. Fi-
nally, combination therapy did not lower bacterial superinfec-
tion rates. Concerning adverse effects, nephrotoxicity was sig-
nificantly less common with b-lactam monotherapy than with
combination therapy (RR, 0.36; 95% CI, 0.28–0.47) [30]. In a
similar study, Safdar et al. [31] evaluated the difference between
the effects of combination therapy and monotherapy on mor-
tality in patients with gram-negative bacteremia. They included
17 studies, encompassing 3077 subjects. The summary OR was
0.96 (95% CI, 0.70–1.32), indicating that there was no mortality
benefit favoring combination therapy [31].
The results of these meta-analyses indicate that combination
therapy does not seem to be necessary for the vast majority of
patients with sepsis caused by gram-negative bacteria. Impor-
tantly, patients receiving an aminoglycoside as a second drug
can experience significantly more adverse effects than their
counterparts receiving monotherapy with a different class of
antibiotics. In practice, uncertainty about the etiologic agent
and its resistance profile may justify combination therapy as
the initial decision for certain high-risk patients. Indeed, weak
evidence argues in favor of a beneficial effect of combination
therapy in the case of P. aeruginosa bacteremia. In one retro-
spective analysis, the use of adequate combination antimicro-
bial therapy as empirical therapy until receipt of the antibio-
gram was associated with better survival than was the use of
monotherapy [32]. In the review by Safdar et al. [31], a sub-
analysis of 5 studies of P. aeruginosa infection showed a 50%
reduction in mortality among patients treated with combina-
tion therapy (OR, 0.50; 95% CI, 0.32–0.79). However, Paul and
Leibovici [33] have emphasized the difficulty in concluding
from this review that combination therapy is advantageous for
the treatment of P. aeruginosa bacteremia. Indeed, 4 of the 5
studies in the meta-analysis included single-aminoglycoside
therapy in the monotherapy arm. Clearly, with the exception
of urinary tract infection, monotherapy with aminoglycosides
is not appropriate for treating gram-negative bacteremia.
COMBINATION THERAPY FOR SEVERE
PNEUMOCOCCAL SEPSIS
A potential benefit of combination therapy for severe pneu-
mococcal bacteremia and sepsis has been shown in several clin-
ical studies [34], although the exact mechanism of this effect
remains unclear (table 2). Several experts already promote com-
bination therapy as the initial option for treating severely ill
patients with community-acquired pneumonia who are at high
risk for pneumococcal bacteremia. However, recently published
data have disputed this view. In a large cohort study, we have
not been able to confirm the survival benefit of combination
therapy in the case of severe pneumococcal sepsis (figure 2)
[35]. Likewise, in another recently published multicenter, ob-
servational study, combination therapy did not decrease the
failure rate among 638 patients with documented pneumo-
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coccal pneumonia [36]. Therefore, other experts are more cau-
tious and underline the urgent need for a controlled trial to
provide more-definitive answers [37]. Until these studies are
available, combination therapy for bacteremic pneumococcal
sepsis should not, in our view, become the standard of care.
Antibiotic therapy should be adjusted to active monotherapy
as soon as susceptibility results are available. In particular, if
S. pneumoniae is identified as the sole pathogen, it seems rea-
sonable to discontinue administration of the macrolide.
CONCLUSIONS
In the present article, we have addressed several questions re-
lated to the effect and selection of adequate antimicrobial ther-
apy for critically ill patients. Clearly, microbiologically adequate
antibiotic therapy for severe infections decreases the excess
mortality and failure rate. The detrimental effects of inadequate
antibiotic therapy seem to become weaker in nonsevere infec-
tions and in infections in the most severely ill patients with
short life expectancies [38]. b-Lactam and aminoglycoside
combination therapy does not seem to improve clinical out-
comes in sepsis caused by gram-negative bacteria. Early com-
bination therapy may be advantageous in the case of severe P.
aeruginosa infection, but more data are required to confirm
this assertion. In particular, future studies should clarify
whether this possible effect is based on the broadening of ther-
apy to ensure adequate antimicrobial coverage and to prevent
the emergence of resistance, rather than on the need for 2
microbiologically agents that are active against P. aeruginosa. A
potential benefit of combination therapy in the treatment of
severe pneumococcal sepsis has also been suggested, but re-
cently published data have disputed this hypothesis. Future
studies should attempt to resolve these controversies (table 3).
Because of space constraints, we were not able to cover other
important related issues, such as questions regarding whether
“broadest-spectrum” empirical regimens (e.g., vancomycin plus
imipenem) should not be used for all critically ill patients (i.e.,
whether and when the gains in effective initial therapy would
be offset by the accelerated emergence of resistance) and
whether therapy in the intensive care unit should not be op-
timized according to patient-specific pharmacokinetic and
pathogen-specific pharmacodynamic parameters [39].
We have identified several knowledge gaps and methodo-
logical limitations in previous studies that should be addressed
in future research (table 3). In particular, many studies have
not adequately estimated the excess mortality due to inadequate
therapy. Removing as much of the confounding as possible so
as to obtain an unbiased estimate of the magnitude of the effect
of inadequate therapy is a key methodological challenge for
future research. Moreover, better risk scores should be devel-
oped to distinguish patients at low risk for infection with mul-
tidrug-resistant pathogens from those for whom broadest-spec-
trum therapy could be truly beneficial. Rapid microbiological
tools are urgently needed to identify drug-resistant pathogens
and improve the adequacy of empirical antibiotic therapy and
patient outcome. We strongly believe that molecular techniques
for the rapid identification of microorganisms and improved
markers of severe infections are the most promising candidates
to improve antibiotic choice and reduce unnecessary treatment.
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